| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $1,998,782 ) |
| | 2024 | 2024 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | U43AA031391 | Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase | 000 | 2 | NIH | 8/5/2024 | $498,851 |
| | 2024 | 2024 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44NS132642 | Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic pain | 000 | 2 | NIH | 8/27/2024 | $1,499,931 |
| | 2024 | 2020 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44NS086343 | IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain | 000 | 5 | NIH | 1/9/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $2,303,329 ) |
| | 2023 | 2023 | AFASCI INC | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | U43AA031391 | Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase | 001 | 1 | NIH | 9/26/2023 | -$483,851 |
| | 2023 | 2023 | AFASCI INC | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | U43AA031391 | Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase | 001 | 1 | NIH | 9/26/2023 | $483,851 |
| | 2023 | 2023 | AFASCI INC | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R43DA059524 | Developing a novel treatment of cocaine use disorder using an IND dual inhibitor of Cav3 channel and soluble epoxide hydrolase | 000 | 1 | NIH | 9/7/2023 | $319,547 |
| | 2023 | 2023 | AFASCI INC | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44NS132642 | Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic pain | 000 | 1 | NIH | 9/7/2023 | $1,499,931 |
| | 2023 | 2023 | AFASCI INC | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | U43AA031391 | Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase | 000 | 1 | NIH | 9/22/2023 | $483,851 |
| | 2023 | 2023 | AFASCI INC | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44NS132642 | Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic pain | 001 | 1 | NIH | 9/21/2023 | -$1,499,931 |
| | 2023 | 2023 | AFASCI INC | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44NS132642 | Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic pain | 001 | 1 | NIH | 9/21/2023 | $1,499,931 |
| | 2023 | 2020 | AFASCI INC | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44EY025913 | Development of a Next Generation Visual Performance Assessment System for Rodents | 000 | 3 | NIH | 11/1/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2020 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44NS086343 | IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain | 000 | 5 | NIH | 5/18/2022 | $0 |
| | 2022 | 2019 | AFASCI INC | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R43HL142315 | Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic | 000 | 2 | NIH | 2/1/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2018 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44AG043203 | Development of patented tricyclic pyrones molecules for the treatment of Alzheimer?s Disease | 000 | 4 | NIH | 6/5/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,183,148 ) |
| | 2020 | 2020 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44EY025913 | Development of a Next Generation Visual Performance Assessment System for Rodents | 000 | 3 | NIH | 7/9/2020 | $691,652 |
| | 2020 | 2020 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44NS086343 | IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain | 001 | 5 | NIH | 8/20/2020 | $1,491,584 |
| | 2020 | 2018 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44AG043203 | Development of patented tricyclic pyrones molecules for the treatment of Alzheimer?s Disease | 000 | 4 | NIH | 1/22/2020 | $0 |
| | 2020 | 2018 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44AG043203 | Development of patented tricyclic pyrones molecules for the treatment of Alzheimer?s Disease | 001 | 4 | NIH | 1/23/2020 | $0 |
| | 2020 | 2018 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44NS086343 | IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain | 000 | 4 | NIH | 3/18/2020 | $0 |
| | 2020 | 2014 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R42HL084990 | Development of an automated noninvasive system for sleep restriction in rodents | 000 | 3 | NIH | 10/1/2019 | -$76 |
| | 2020 | 2014 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44DA031578 | Nicotine delivery to rodent with lung alveolar region-targeted aerosol technology | 000 | 3 | NIH | 10/1/2019 | -$12 |
|
| Issue Date FY: 2019 ( Subtotal = $1,038,314 ) |
| | 2019 | 2019 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44EY025913 | Development of a Next Generation Visual Performance Assessment System for Rodents | 000 | 2 | NIH | 4/23/2019 | $788,405 |
| | 2019 | 2019 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R43HL142315 | Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic | 000 | 2 | NIH | 7/11/2019 | $149,520 |
| | 2019 | 2019 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R43HL142315 | Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic | 001 | 2 | NIH | 7/15/2019 | $100,389 |
| | 2019 | 2019 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R43HL142315 | Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic | 002 | 2 | NIH | 8/16/2019 | -$100,389 |
| | 2019 | 2019 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R43HL142315 | Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic | 004 | 2 | NIH | 9/17/2019 | $0 |
| | 2019 | 2019 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R43HL142315 | Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic | 003 | 2 | NIH | 9/16/2019 | $0 |
| | 2019 | 2019 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R43HL142315 | Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic | 002 | 2 | NIH | 8/16/2019 | $100,389 |
| | 2019 | 2018 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44NS086343 | IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain | 001 | 4 | NIH | 7/17/2019 | $0 |
| | 2019 | 2016 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R41DA041003 | Sample-free onsite detection of cocaine using microneedles via laser-treated skin | 000 | 1 | NIH | 10/27/2018 | $0 |
| | 2019 | 2016 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44NS086343 | IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain | 000 | 3 | NIH | 12/14/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $2,843,119 ) |
| | 2018 | 2018 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44AG043203 | Development of patented tricyclic pyrones molecules for the treatment of Alzheimer?s Disease | 001 | 4 | NIH | 9/20/2018 | $240,927 |
| | 2018 | 2018 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44AG043203 | Development of patented tricyclic pyrones molecules for the treatment of Alzheimer?s Disease | 000 | 4 | NIH | 2/12/2018 | $960,706 |
| | 2018 | 2018 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44NS086343 | IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain | 001 | 4 | NIH | 9/15/2018 | $1,491,977 |
| | 2018 | 2018 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R43HL142315 | Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic | 000 | 1 | NIH | 9/17/2018 | $149,520 |
| | 2018 | 2016 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44NS086343 | IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain | 000 | 3 | NIH | 6/27/2018 | $0 |
| | 2018 | 2016 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R43DE026094 | Developing a novel CGRP antagonist for treatment of dental neuroinflammatory pain | 000 | 1 | NIH | 8/13/2018 | $0 |
| | 2018 | 2016 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44NS086343 | IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain | 002 | 3 | NIH | 9/17/2018 | $0 |
| | 2018 | 2015 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R41EY025913 | A Visual Assessment System for Retinal Function/Drug Discovery | 000 | 1 | NIH | 2/8/2018 | $0 |
| | 2018 | 2014 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R43AG043203 | Development of Novel Tricyclic Pyrone Drugs for Treatment of Alzheimer Disease | 000 | 2 | NIH | 9/17/2018 | -$7 |
| | 2018 | 2013 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44DA026363 | Treat Neuropathic Pain with Dissolvable Microneedles Containing Anti-CGRP Peptide | 000 | 3 | NIH | 9/30/2018 | -$4 |
|
| Issue Date FY: 2017 ( Subtotal = $973,078 ) (Continued on the next page) |
| | 2017 | 2017 | AFASCI, INC. | 2633 MARTINEZ DR | BURLINGAME | CA | 94010-5828 | SAN MATEO | USA | R44AG043203 | Development of patented tricyclic pyrones molecules for the treatment of Alzheimer?s Disease | 000 | 3 | NIH | 2/28/2017 | $973,076 |
|
